StockData
Decoy Therapeutics Inc. logo

Decoy Therapeutics Inc. (DCOY) shareholders

DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$0.95+0.05 (+5.37%)

Close on Nov 17, 2026Market cap $622.03KP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.7%
0M of 1M shares
Institutional holders
4
2 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
2 buys · 2 sales
Net bought $19.73K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
CVI Investments, Inc.
Joint filing with Heights Capital Management, Inc. (9.90%)
708,5659.90%13G (passive) amendmentDec 31, 2025
Heights Capital Management, Inc.
Joint filing with CVI Investments, Inc. (9.90%)
362,4999.90%13G (passive)Nov 11, 2025
Steven Boyd
Joint filing with Armistice Capital, LLC (9.99%)
65,5039.99%13G (passive)Jun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of DCOYValueChange% of portfolio
Vanguard Capital Management LLC4,0340.62%$29.00KNew0.00%
Tower Research Capital LLC (TRC)2560.04%$1.84K−7650.00%
UBS Group AG250.00%$180−5210.00%
Caitong International Asset Management Co., Ltd20.00%$14New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202640M0.7%2 / 02 / 20M0M
Q1 202640M0.2%4 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

FundShares% of DCOYValue% of fundAs of
Fidelity Extended Market Index Fund5,1560.79%$45.89K0.00%May 31, 2026
Vanguard Extended Market Index Fund4,0340.62%$29.00K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund4770.07%$4.25K0.00%May 31, 2026
Horizon Kinetics Medical ETF210.00%$1490.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Frederick Pierce IiChief Executive Officer34,8445.32%Sep 2, 2026
Mark J. RosenblumChief Financial Officer11,3631.73%Sep 2, 2026
Peter Klaus MarschelChief Business Officer3,9000.60%Sep 2, 2026
Barbara Louise HibnerChief Scientific Officer4,2160.64%Sep 2, 2026
William K. McVicarDirector4,0640.62%Sep 2, 2026
Patricia G. GauthierDirector2,0000.31%Sep 2, 2026
Jonathan I. LieberDirector2,0020.31%Sep 2, 2026
Arnold C. HanishDirector8,4181.28%Sep 2, 2026
Tess BurlesonDirector2,0020.31%Sep 2, 2026
Paul LammersDirector2,0010.31%Sep 2, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jonathan I. Lieber
Director
Aug 31, 2026Award+2,000––2,002
William K. McVicar
Director
Aug 31, 2026Award+3,000––3,002
Arnold C. Hanish
Director
Aug 31, 2026Award+3,000––3,418
Paul Lammers
Director
Aug 31, 2026Award+2,000––2,001
Frederick Pierce Ii
Chief Executive Officer
Aug 31, 2026Award+33,455––34,844
Patricia G. Gauthier
Director
Aug 31, 2026Award+2,000––2,000
Barbara Louise Hibner
Chief Scientific Officer
Aug 31, 2026Award+4,216––4,216
Peter Klaus Marschel
Chief Business Officer
Aug 31, 2026Award+3,900––3,900
Tess Burleson
Director
Aug 31, 2026Award+2,000––2,002
Mark J. Rosenblum
Chief Financial Officer
Aug 31, 2026Award+9,682––11,363
Arnold C. Hanish
Director
Dec 30, 2025Sale−12$0.64$80
Arnold C. Hanish
Director
Dec 30, 2025Sale−15$0.64$105,000
Arnold C. Hanish
Director
Nov 20, 2025Buy+5,000$0.75$3.75K5,015
Mark J. Rosenblum
Exec VP Finance, CFO
Nov 20, 2025Buy+20,000$0.80$16.00K20,177
Mark J. Rosenblum
Exec VP Finance, CFO
Feb 13, 2023Award+6,432––21,851
David J. Arthur
Chief Executive Officer, Director
Feb 13, 2023Award+14,300––48,019
William K. McVicar
Director
Jan 3, 2023Award+1,440––1,788
Jonathan I. Lieber
Director
Jan 3, 2023Award+1,440––2,940
David J. Arthur
Chief Executive Officer, Director
Jan 3, 2023Award+20,000––33,719
Paul Lammers
Director
Jan 3, 2023Award+1,440––1,718
Tess Burleson
Director
Jan 3, 2023Award+1,440––2,722
Mark J. Rosenblum
Exec VP Finance, CFO
Jan 3, 2023Award+8,000––15,419
Bruce J. McCreedy Jr.
Director
Jan 3, 2023Award+1,440––1,788
Arnold C. Hanish
Director
Jan 3, 2023Award+1,440––1,440
Mark J. Rosenblum
Exec VP Finance, CFO
Nov 3, 2022Award+1,488$1.73$2.57K7,419
David J. Arthur
Chief Executive Officer, Director
Nov 3, 2022Award+2,693$1.73$4.66K13,719
Mark J. Rosenblum
Exec VP Finance, CFO
Nov 3, 2022Award+7,314$1.73$12.65K13,245
David J. Arthur
Chief Executive Officer, Director
Nov 3, 2022Award+10,000$1.73$17.30K21,026
David J. Arthur
Chief Executive Officer, Director
Nov 3, 2022Award+10,000$1.73$17.30K285,674
Mark J. Rosenblum
Exec VP Finance, CFO
Nov 3, 2022Award+7,314$1.73$12.65K155,633
Jonathan I. Lieber
Director
Jun 7, 2022Buy+37,500$0.19$7.13K37,500
Tess Burleson
Director
Jun 7, 2022Buy+27,700$0.18$4.99K32,050
William K. McVicar
Director
Jun 6, 2022Buy+26,553$0.19$5.05K26,553
Arnold C. Hanish
Director
Jun 3, 2022Buy+28,000$0.18$5.04K46,350
Mark J. Rosenblum
Exec VP Finance, CFO
May 31, 2022Buy+28,000$0.18$5.04K148,319
David J. Arthur
Chief Executive Officer, Director
May 26, 2022Buy+708$0.18$127282,382
David J. Arthur
Chief Executive Officer, Director
May 26, 2022Buy+18,600$0.18$3.35K281,674
David J. Arthur
Chief Executive Officer, Director
May 26, 2022Buy+3,400$0.18$612263,074
David J. Arthur
Chief Executive Officer, Director
May 26, 2022Buy+10,800$0.18$1.94K303,574
David J. Arthur
Chief Executive Officer, Director
May 26, 2022Buy+10,392$0.18$1.87K292,774
Mark J. Rosenblum
Exec VP Finance, CFO
May 3, 2022Award+10,000$0.19$1.90K120,319
David J. Arthur
Chief Executive Officer, Director
May 3, 2022Award+10,000$0.19$1.90K259,674
David J. Arthur
Chief Executive Officer, Director
Mar 3, 2022Buy+139,488$0.39$54.40K249,674
Mark J. Rosenblum
Exec VP Finance, CFO
Mar 3, 2022Buy+76,246$0.39$29.74K110,319
Mark J. Rosenblum
Exec VP Finance, CFO
Nov 3, 2021Award+7,787$0.72$5.61K34,073
David J. Arthur
Chief Executive Officer, Director
Nov 3, 2021Award+7,939$0.72$5.72K110,186
David J. Arthur
Chief Executive Officer, Director
Aug 17, 2021Buy+2,000$0.89$1.78K102,247
David J. Arthur
Chief Executive Officer, Director
Aug 17, 2021Buy+2,000$0.90$1.80K100,247
Arnold C. Hanish
Director
Aug 10, 2021Buy+7,000$0.88$6.16K18,350
David J. Arthur
Chief Executive Officer, Director
May 3, 2021Award+9,822$0.57$5.60K96,247
Mark J. Rosenblum
Exec VP Finance, CFO
May 3, 2021Award+9,563$0.57$5.45K26,286
David J. Arthur
Chief Executive Officer, Director
Nov 3, 2020Award+4,879$0.56$2.73K86,425
Mark J. Rosenblum
Exec VP Finance, CFO
Nov 3, 2020Award+4,723$0.56$2.64K16,723
Arnold C. Hanish
Director
Aug 21, 2020Buy+4,000$0.98$3.92K11,350
Arnold C. Hanish
Director
Aug 21, 2020Buy+4,000$0.98$3.92K11,350
David J. Arthur
Chief Executive Officer, Director
Aug 19, 2020Buy+1,000$1.01$1.01K2,000
David J. Arthur
Chief Executive Officer, Director
Aug 19, 2020Buy+1,000$1.01$1.01K1,000
Mark J. Rosenblum
Exec VP Finance, CFO
Aug 17, 2020Buy+5,000$1.00$5.00K12,000
Mark J. Rosenblum
Exec VP Finance, CFO
Feb 19, 2020Buy+2,000$0.95$1.90K7,000
Scott Jordan
Chief Business Officer
Feb 18, 2020Buy+11,300$0.90$10.17K31,609

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
17.18%
0M shares short
Days to cover
1.8
At 0M shares a day
Change since last report
+2.2%
From 0M shares
Short volume, 20 days
32.3%
Of volume reported to FINRA

Shares sold short, last 10 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Decoy Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 764,407 shares on Sep 23, 2026 over the last 90 days.

See a number that looks wrong?